These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 24690004)

  • 1. Directing the immune system with chemical compounds.
    Mancini RJ; Stutts L; Ryu KA; Tom JK; Esser-Kahn AP
    ACS Chem Biol; 2014 May; 9(5):1075-85. PubMed ID: 24690004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overview and outlook of Toll-like receptor ligand-antigen conjugate vaccines.
    Fujita Y; Taguchi H
    Ther Deliv; 2012 Jun; 3(6):749-60. PubMed ID: 22838070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toll-like Receptor Agonist Conjugation: A Chemical Perspective.
    Ignacio BJ; Albin TJ; Esser-Kahn AP; Verdoes M
    Bioconjug Chem; 2018 Mar; 29(3):587-603. PubMed ID: 29378134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of immune responses through direct activation of Toll-like receptors to T cells.
    Liu G; Zhang L; Zhao Y
    Clin Exp Immunol; 2010 May; 160(2):168-75. PubMed ID: 20128825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent Findings on the Application of Toll-like Receptors Agonists in Cancer Therapy.
    Mikulandra M; Pavelic J; Glavan TM
    Curr Med Chem; 2017; 24(19):2011-2032. PubMed ID: 28322156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants.
    Maisonneuve C; Bertholet S; Philpott DJ; De Gregorio E
    Proc Natl Acad Sci U S A; 2014 Aug; 111(34):12294-9. PubMed ID: 25136133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system.
    Engel AL; Holt GE; Lu H
    Expert Rev Clin Pharmacol; 2011 Mar; 4(2):275-89. PubMed ID: 21643519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toll-like receptors in human papillomavirus infection.
    Zhou Q; Zhu K; Cheng H
    Arch Immunol Ther Exp (Warsz); 2013 Jun; 61(3):203-15. PubMed ID: 23435874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioconjugation Approaches to Producing Subunit Vaccines Composed of Protein or Peptide Antigens and Covalently Attached Toll-Like Receptor Ligands.
    Xu Z; Moyle PM
    Bioconjug Chem; 2018 Mar; 29(3):572-586. PubMed ID: 28891637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural Properties of Potential Synthetic Vaccine Adjuvants - TLR Agonists.
    Honegr J; Soukup O; Doležal R; Malinak D; Penhaker M; Prymula R; Kuca K
    Curr Med Chem; 2015; 22(29):3306-25. PubMed ID: 26295466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drugs targeting Toll-like receptors.
    Krishnan J; Lee G; Choi S
    Arch Pharm Res; 2009 Nov; 32(11):1485-502. PubMed ID: 20091261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of defined TLR ligands as adjuvants within human vaccines.
    Duthie MS; Windish HP; Fox CB; Reed SG
    Immunol Rev; 2011 Jan; 239(1):178-96. PubMed ID: 21198672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic targeting of the innate immune system in domestic animals.
    Coffey TJ; Werling D
    Cell Tissue Res; 2011 Jan; 343(1):251-61. PubMed ID: 20953632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combinatorial Delivery of Dual and Triple TLR Agonists via Polymeric Pathogen-like Particles Synergistically Enhances Innate and Adaptive Immune Responses.
    Madan-Lala R; Pradhan P; Roy K
    Sci Rep; 2017 May; 7(1):2530. PubMed ID: 28566683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Syk-Card9-activating C-type lectin receptors by vaccine adjuvants: findings, implications and open questions.
    Lang R; Schoenen H; Desel C
    Immunobiology; 2011 Nov; 216(11):1184-91. PubMed ID: 21742403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toll-Like Receptor Agonists as Adjuvants for Allergen Immunotherapy.
    Kirtland ME; Tsitoura DC; Durham SR; Shamji MH
    Front Immunol; 2020; 11():599083. PubMed ID: 33281825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential Effects of Toll-Like Receptor Signaling on the Activation of Immune Responses in the Upper Respiratory Tract.
    Xu M; Li N; Fan X; Zhou Y; Bi S; Shen A; Wang B
    Microbiol Spectr; 2022 Feb; 10(1):e0114421. PubMed ID: 35196817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthetic vaccines: the role of adjuvants in immune targeting.
    Jiang ZH; Koganty RR
    Curr Med Chem; 2003 Aug; 10(15):1423-39. PubMed ID: 12871139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toll-like receptor agonists: are they good adjuvants?
    Gnjatic S; Sawhney NB; Bhardwaj N
    Cancer J; 2010; 16(4):382-91. PubMed ID: 20693851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The potential use of Toll-like receptor (TLR) agonists and antagonists as prophylactic and/or therapeutic agents.
    Makkouk A; Abdelnoor AM
    Immunopharmacol Immunotoxicol; 2009; 31(3):331-8. PubMed ID: 19555209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.